NXT Post-Market Clinical Follow-up

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorLaborie Medical Technologies Inc.

About this trial

NXT Urodynamics System Post-Market Clinical Follow-up Clinical Investigation to Confirm Ongoing Safety and Performance in Urodynamic Patient Sub-Populations

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients medically indicated for urodynamic study

Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements

Disqualifiers

Patients or legally authorized representative with cognitive or psychiatric condition that interferes with or precludes direct and accurate communication regarding the study, giving informed consent or ability to complete the patient questionnaire

Patients with confirmed active bladder infections (not including patients with asymptotic bacteria)

Pregnant women

Patients with recent (less than 2 weeks) pelvic floor surgery

Trial population

Male, Female and Pediatric subjects who have been medically indicated for UDS testing.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Urodynamic procedure

    Diagnostic test

    Urodynamic procedure

Treatment groups

180 Participants
are divided into 6 treatment groups

6

Treatment groups

See each treatment group below.

Group A: Pediatric1 intervention
Group B: Male Adult Obstructive0 interventions
Group C: Male Adult Incontinence and/or Overactive Bladder1 intervention
Group D: Female Adult Obstructive0 interventions
Group E: Female Adult Incontinence and/or Overactive Bladder1 intervention
Group F: Adults with Neurological Co-morbidities0 interventions

Trial outcomes

Primary outcomes

1

Assess NXT system performance

Assess the proportion of affirmative responses to the question: did the NXT system successfully measure all necessary urodynamic parameters you required for this patient?

Time frame
120 Minutes
2

Assess NXT system safety

The primary safety endpoint will be measured by recording the incidence of serious adverse events and adverse events.

Time frame
120 Minutes

Secondary outcomes

1

Assess NXT system performance

Assess the proportion of affirmative responses to the question: Was the urodynamic study completed without any technical failure that prevented its completion?

Time frame
120 Minutes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.